NCT07735897Not yet recruiting
Long Term Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women
Prospective Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women With Hormone-sensitive Breast Cancer Who Remain Premenopausal or Resume Menstruation After Chemotherapy: ASTRRA- IV Study
Source: ClinicalTrials.gov · Last updated 31 Jul 2026
Brief summary (registry, in English)
This study evaluates the long-term effects of adding 2 years of ovarian function suppression (OFS) to tamoxifen therapy in young premenopausal women with hormone receptor-positive breast cancer after chemotherapy. The study will assess recurrence, breast cancer-specific survival, and overall survival beyond 10 years to determine the long-term benefits of OFS treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 1483 (estimated)
- First submitted
- 25 Jul 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 1 Mar 2034
- Lead sponsor
- MedicalExcellence
- Diseases
- Ovarian cancer
- NCT number
- NCT07735897
What you commit to
- Study type: Observational
- Planned participants: 1483
- From 1 Jul 2026 to the primary completion date, 1 Mar 2034
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with primary breast cancer meeting any of the following criteria:
- Hormone receptor-negative breast cancer Unknown hormone receptor status
- Patients with a history of hysterectomy or bilateral oophorectomy
- Patients with breast sarcoma or squamous cell carcinoma of the breast
- Patients with a history of malignancy other than breast cancer within 5 years prior to enrollment
- Patients with thrombocytopenia
- Patients who had previously received CMF chemotherapy (cyclophosphamide, methotrexate, and fluorouracil)
Who the study is looking for
- Premenopausal women with hormone receptor-positive breast cancer enrolled in the ASTRRA trial (NCT00912548).
- Patients enrolled and randomized in the ASTRRA study between March 1, 2009, and July 17, 2018 (excluding screening failures).
- Patients with available long-term follow-up information.
Age in the registry: 20 years to 45 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asan Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.